Aktuellt
SENASTE
Redeye briefly comments on Tumorad (SN201) completing preclinical safety studies, bringing the drug candidate one step closer to phase I/II clinical trials in 2022. Today's news was in line with our expectations of the drug candidate entering clinical studies next year. Nevertheless, we are encouraged by Tumorad's preclinical development proceeding according to plan and our confidence in the clinical trial starting according to our expected timeline has increased. As we advance, we understand that Spago can now proceed to writing and submitting clinical trial applications. Based on the timing of today's news, we guess Spago's clinical trial application could be approved around mid-2022, with a potential trial commencing in H2 2022.
LÄS MER
